Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

Please use this identifier to cite or link to this item: https://essuir.sumdu.edu.ua/handle/123456789/87802

Or use following links to share this resource in social networks: Recommend this item

Title	Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Authors	Felip, E. Altorki, N.K. Zhou, C. Vallieres, E. Vynnychenko, Ihor Oleksandrovych Akopov, A. Martinez-Marti, A. Chella, A. Bondarenko, I. Ursol, G. Levchenko, E. Kislov, N. Liersch, R. Belleli, R. McNally, V.A. Bennett, E. Gitlitz, B.J. Wakelee, H.
ORCID	http://orcid.org/0000-0002-2339-6509
Keywords	IMpower010 present further analyses
Type	Conference Papers
Date of Issue	2022
URI	https://essuir.sumdu.edu.ua/handle/123456789/87802
Publisher	Elsevier
License	Creative Commons Attribution 4.0 International License
Citation	Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study / E. Felip, N. K. Altorki, C. Zhou et al. // Annals of Oncology. 2022. Volume 33, Issue S2. S 71.
Abstract	IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC 50% stage II-IIIA NSCLC pts.
Appears in Collections:	Наукові видання (НН МІ)